ArticleThe Annals of pharmacotherapy2022
The Safety of Continuous Infusion Propofol in Mechanically Ventilated Adults With Coronavirus Disease 2019.
Article in The Annals of pharmacotherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05336656 (Assessment of Analgesics and Sedatives in Mechanically Ventilated Patients With COVID-19), which is not on this map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Assessment of Analgesics and Sedatives in Mechanically Ventilated Patients With COVID-19
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- Propofol and Hypertriglyceridemia in the ICU: A Systematic Review and Meta-Analysis of Recent Observational Data.Cureus · 2026Review
- Pharmacovigilance and toxicological studies on safety signals associated with the combined use of propofol and midazolam.BMC anesthesiology · 2026Article
- Hemodynamic Effects of Guideline-Based Sedation in Mechanically Ventilated Adults: A Multicenter Observational Analysis.Critical care explorations · 2025Observational
- Identification of Distinct Biological Groups of Patients With Cryptogenic NORSE via Inflammatory Profiling.Neurology(R) neuroimmunology & neuroinflammation · 2025Article
- Food for Thought: Toward a More Nuanced Approach to Propofol-associated Hypertriglyceridemia.Annals of the American Thoracic Society · 2025Article
- Propofol-Related Infusion Syndrome: A Bibliometric Analysis of the 100 Most-Cited Articles.Cureus · 2023Review
- Role of Cytochrome P450 2C9 in COVID-19 Treatment: Current Status and Future Directions.European journal of drug metabolism and pharmacokinetics · 2023Review
- Unusual case of propofol-related infusion syndrome complicating severe COVID-19 ARDS.BMJ case reports · 2023Article
- Triglyceride Concentrations and Their Relationship to Sedation Choice and Outcomes in Mechanically Ventilated Patients Receiving Propofol.Annals of the American Thoracic Society · 2023Observational
- Propofol infusion syndrome & COVID-19 in a victim of multiple gunshot wounds: Diagnostic and therapeutic dilemmas.Trauma case reports · 2022Article
- Post-treatment with propofol inhibits inflammatory response in LPS-induced alveolar type II epithelial cells.Experimental and therapeutic medicine · 2022Article
- An architecture for research computing in health to support clinical and translational investigators with electronic patient data.Journal of the American Medical Informatics Association : JAMIA · 2022Article
- How to Manage Withdrawal of Sedation and Analgesia in Mechanically Ventilated COVID-19 Patients?Journal of clinical medicine · 2021Review
Corrections and comments
- Commented on by
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundPropofol is commonly used to achieve ventilator synchrony in critically ill patients with coronavirus disease 2019 (COVID-19), yet its safety in this patient population is unknown.
objectiveTo evaluate the safety, in particular the incidence of hypertriglyceridemia, of continuous infusion propofol in patients with COVID-19.
methodsThis was a retrospective study at 1 academic medical center and 1 affiliated teaching hospital in New York City. Adult, critically ill patients with COVID-19 who received continuous infusion propofol were included. Patients who received propofol for <12 hours, were transferred from an outside hospital while on mechanical ventilation, or did not have a triglyceride concentration obtained during the infusion were excluded.
resultsA total of 252 patients were included. Hypertriglyceridemia (serum triglyceride concentration ≥ 400 mg/dL) occurred in 38.9% of patients after a median cumulative dose of 4307 mg (interquartile range [IQR], 2448-9431 mg). The median time to triglyceride elevation was 3.8 days (IQR, 1.9-9.1 days). In the multivariable regression analysis, obese patients had a significantly greater odds of hypertriglyceridemia (odds ratio = 1.87; 95% CI = 1.10, 3.21). There was no occurrence of acute pancreatitis. The incidence of possible propofol-related infusion syndrome was 3.2%. CONCLUSION AND RELEVANCE: Hypertriglyceridemia occurred frequently in patients with COVID-19 who received propofol but did not lead to acute pancreatitis. Elevated triglyceride concentrations occurred more often and at lower cumulative doses than previously reported in patients without COVID-19. Application of these data may aid in optimal monitoring for serious adverse effects of propofol in patients with COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.